VP, Translational Medicine
Posted on: November 20, 2023
Work_Category - hybrid Description
The VP, Translational Medicine is a leadership position within the
Research organization. Primary responsibilities include identifying
indications for a portfolio of preclinical targets along with
creating initial clinical development plans to expedite filing of
CTAs/INDs with the strongest basis for proof of concept in Phase 1.
The current Alnylam portfolio is therapeutic area agnostic, and
currently spans cardiometabolic, neurological, orphan, renal, and
ocular diseases with plans to expand into numerous other
indications and tissues.
The successful candidate will play a central role in the
identification of new targets from multiple sources including
Alnylam's extensive access to large genotype-phenotype datasets
(e.g., UK biobank and Our Future Health), scientific literature and
by working with Research teams engaged in novel biological research
related to putative targets. The role will also be critical in the
identification of preclinical and clinical biomarkers and help
create momentum for programs being driven to the clinic. This is a
new role within Research with the potential to form a group after
In addition, the VP, Translational Medicine will foster key
strategic partnerships and be responsible for the
Research/nonclinical and Clinical Development interfaces, ensuring
awareness/alignment of the preclinical portfolio, indication
strategy and development plans. Externally, this position is
expected to be active in garnering support for the pipeline,
including at Alnylam's annual R&D Day, and helping build strong
relationships with world class key opinion leaders including
setting up KOL panels and other key interactions.
Summary of Key Responsibilities
- Identify targets/indications where Alnylam technology can
deliver transformative medicines.
- Lead cross-functional teams to identify and prioritize
indications for targets within Research.
- Drive external interactions with key opinion leaders to develop
indication and early clinical strategy and identify targets and
diseases of interest.
- Help make prioritization decisions around the internal
- Create Phase 1 clinical development plans that enable robust
assessment of pharmacodynamics and provide early indications of
efficacy (where possible).
- Ensure program readiness for Phase 1 by driving biomarker
- Actively participate in target discovery efforts including
working closely with the statistical genetics team to enable
discovery of new targets from genotype-phenotype datasets.
- Lead the interface with Clinical Development to ensure smooth
transition of discovery programs into the clinic and alignment with
- Work closely with commercial and portfolio management functions
to optimize the indications for preclinical assets in line with
Alnylam's broader strategy.
- MD or MD/PhD with Board certification in internal medicine or
- 10+ years of industry experience.
- Proven track record of leading targets from research to
- Experience in bench/lab work and a strong track record of
- Inquisitive, discovery mindset with experience in early
clinical development and discovery research.
- Expertise in development of Phase 1 development plans and
- Passion for biomarker discovery and development in the context
of fast-moving research programs.
- Comfort and experience with target discovery from animal models
to human genetic datasets.
- Inter-personal skills with a highly collaborative approach to
achieving goals critical.
- Demonstrated ability to work effectively across the
- Excellent communication and presentation skills are necessary
to represent team efforts at key internal governance meetings,
including a world-class SAB
and externally in various scientific and other forums.
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of
RNA interference (RNAi) into a whole new class of innovative
medicines with the potential to transform the lives of people
afflicted with rare and more prevalent diseases. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach to treating diseases at their genetic
source by "interfering" with mRNA that cause or contribute to
disease. Since our founding in 2002, Alnylam has led the RNAi
Revolution and continues to turn scientific possibility into
Our people-first culture is guided by our core values: fiercely
innovative, open culture, purposeful urgency, passion for
excellence, and commitment to people, and these values influence
how we work and the business decisions we make. Thanks to feedback
from our employees over the years, we've been fortunate to be named
a top employer around the world. Alnylam is extremely proud to have
been recognized as the #1 Large Employer by Boston Globe Top Places
to Work in 2022, one of Science Magazine's Top Biopharma Employers,
one of America's Most Responsible Companies for 2023 by Newsweek, a
Fast Company Best Workplace for Innovators, and a Great Place to
Work in Canada, France, Italy, Spain, Switzerland, and UK - among
At Alnylam, we commit to an inclusive recruitment process and equal
employment opportunity. We are dedicated to building an environment
where employees can feel that they belong, can bring their
authentic selves to work, and achieve to their full potential. By
empowering employees to embrace their unique differences at work,
our business grows stronger with advanced and original thinking,
allowing us to bring groundbreaking medicines to patients.
Qualified applicants will receive consideration for employment
without regard to their race, color, religion, age, sex, sexual
orientation, gender identity or expression, national origin,
ethnicity, marital status, protected veteran status, disability, or
any other characteristics prohibited by law. Alnylam is an E-Verify
Keywords: Alnylam, Cambridge , VP, Translational Medicine, Healthcare , Cambridge, Massachusetts
Didn't find what you're looking for? Search again!